NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus

Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy

Houston, Texas–(Newsfile Corp. – October 16, 2026) – NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program, is breathing independently without ventilator support and beginning to move his legs. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians and the Department of Health – Abu Dhabi.

The report places NEO100 in the spotlight while highlighting the unmet medical needs that continue to drive experimental approaches to aggressive central nervous system cancers. For NeOnc, the strategic significance extends beyond a single patient: the company is seeking to advance a therapy for serious diseases in which existing treatment options may offer insufficient benefit, particularly for patients who have not responded adequately to available interventions. However, the reported improvement in this individual case should be interpreted cautiously. A compassionate-use experience involving one patient cannot determine the treatment’s efficacy or predict outcomes for other patients. Those questions will require carefully controlled clinical research.

Nevertheless, the case illustrates the difficult balance between scientific rigor and the urgent needs of patients with life-threatening illnesses. Compassionate-use access can provide a treatment opportunity when conventional options are limited, while also underscoring the importance of generating reliable evidence about safety, dosage and therapeutic benefit. NeOnc’s challenge is to translate the rationale behind its investigational approach into reproducible clinical results, especially in the hardest-to-treat cases where the need for additional options is greatest.

A Difficult Clinical Challenge Could Define NEO100’s Development Path

Aggressive brain tumors remain among the most challenging cancers to treat because of the complexity of the central nervous system, the limitations of drug delivery to brain tissue and the difficulty of achieving durable disease control. Patients whose tumors progress despite existing therapies face particularly limited choices, creating a compelling medical rationale for investigating new treatment strategies.

NeOnc is positioning its development program around this unmet need. Its investigational intranasal NEO100 is intended to offer an alternative delivery approach for central nervous system disease, while the company continues to evaluate its clinical potential through formal studies and regulatory engagement. The pediatric compassionate-use report adds a human dimension to that work.

An early improvement in breathing or movement is clinically noteworthy, particularly in a critically ill child, and the experience highlights why investigational therapies continue to attract attention in settings where available treatments have failed to meet patients’ needs.

For NeOnc, the most important milestone will be demonstrating that the scientific rationale for NEO100 translates into measurable outcomes through appropriately designed clinical trials.

Abu Dhabi Becomes Strategic Clinical and Regulatory Development Center

NeOnc’s progress in the United Arab Emirates provides a broader institutional context for its clinical ambitions. In June 2026, the Department of Health – Abu Dhabi granted investigational new drug authorizations covering NEO100 protocols for adult development and a pediatric pathway subject to further protocol review. These regulatory developments provide a framework for advancing the company’s work in the region, while the pediatric compassionate-use case demonstrates the importance of coordination among physicians, regulators and the company when considering access for an individual patient.

NEO100 also received U.S. Food and Drug Administration Rare Pediatric Disease Designation in March 2025 for pediatric-type diffuse high-grade gliomas.

Together, the U.S. designation and Abu Dhabi regulatory activity illustrate NeOnc’s effort to establish a development pathway that reaches beyond a single jurisdiction. International clinical development can create opportunities to engage with different medical institutions and regulatory authorities. The company’s ability to coordinate these activities while maintaining consistent clinical standards will be an important consideration as its programs advance.

Phase 2a Data Provide Clinical Benchmark

Beyond the compassionate-use update, NeOnc’s existing clinical results offer another reference point for evaluating NEO100’s development prospects. In August, the company reported topline results from a 24-patient Phase 2a study of NEO100, including six-month progression-free survival of 48.9% and median overall survival of 26.09 months.

These results provide a quantitative basis for further discussion of the candidate’s clinical potential. However, interpreting them requires attention to the study population, design, patient characteristics, follow-up period and statistical limitations.

This question is particularly relevant to NeOnc’s stated focus on serious brain cancers with substantial unmet needs, including situations in which patients have not responded adequately to available treatment options.

NEO212 Adds Second Development Program

NeOnc is also advancing NEO212, its oral investigational candidate, which has completed Phase 1 dose escalation and is progressing toward potential Phase 2 development. The program represents a separate component of the company’s development strategy and gives NeOnc another opportunity to generate clinical evidence within its broader central nervous system oncology portfolio.

The next major scheduled regulatory milestone is the November 17 FDA End-of-Phase 1 Type B meeting for NEO212. NeOnc expects to discuss potential next steps in the program’s development. The outcome of that regulatory interaction could help clarify the path toward a potential Phase 2 study.

Banking Appointment Adds Institutional and Financial Experience

NeOnc’s broader strategy also includes strengthening its governance and institutional relationships. The company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to its Board of Directors. Alabedin brings more than three decades of international banking and executive experience.

The appointment is notable because NeOnc’s development ambitions involve more than laboratory research and clinical trials. Advancing investigational therapies across international markets can require substantial capital, regulatory coordination, partnerships with medical institutions and careful financial oversight. A director with extensive experience in banking and international business may contribute relevant perspectives as the company evaluates financing requirements, institutional relationships and potential strategic opportunities.

FAB reported AED 1.41 trillion in total assets as of June 30, 2026.

Financing and Capital Structure Remain Important Considerations

NeOnc also completed a $15 million registered direct offering and announced the redemption of its outstanding Series A convertible preferred stock. According to the company, the redemption eliminated the potential dilution associated with those preferred shares without issuing common stock in the redemption.

The $15 million offering provides an additional financing data point, while the preferred-stock redemption addresses a specific potential source of dilution.

For a biotechnology company pursuing multiple investigational therapies across international markets, the relationship between scientific progress and capital allocation is central. Clinical milestones can strengthen the basis for future strategic discussions, but they also create new requirements for funding, execution and regulatory compliance.

About Wall Street PR

Wall Street PR (WSTPR) is your premier destination for intelligent investor relations and financial communications. We deliver meticulously curated market intelligence, breaking news alerts, exclusive expert insights, and in-depth analysis to help investors and traders stay ahead in today’s fast-moving markets. Whether you’re a seasoned professional or an emerging investor, our platform provides hard-to-find information on earnings reports, regulatory shifts, market trends, and emerging opportunities, empowering you to make confident, well-informed decisions.

For companies, we specialize in high-impact Investor and Public Relations. We transform significant corporate milestones into compelling stories that resonate with investors, analysts, and the media. Our experienced team crafts strategic press releases and communications that cut through the noise, ensuring your achievements reach major outlets such as Forbes, Barron’s, Investor’s Business Daily, The Wall Street Journal, and beyond. With superior reach across more than 7,500 media outlets and strong relationships with influential financial newsletter writers, we maximize visibility and deliver your message clearly, whether celebrating success or navigating challenges.

Through targeted distribution, email newsletters, and strategic storytelling, Wall Street PR helps public companies build credibility, engage shareholders, and enhance market presence with precision and professionalism.

For further information, please go to https://wallstreet-pr.com/.

Important Note

Our coverage is catalyst-driven and time-sensitive. We may not provide continuous updates or long-term monitoring. Readers should conduct their own due diligence, as material changes can occur after publication.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. WSTPR is a third-party media provider that has been compensated for providing ongoing NTHI market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further info https://wallstreet-pr.com/disclosure-nhti/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319351